---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-24-000124"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:29:46.069073+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q1 net sales $606.7M (+119% YoY); raises FY2024 guidance

## Summary
- Net sales $606.7M, up 119.3% YoY, driven by NuVasive addition and higher spine/enabling tech volumes.
- GAAP net loss $7.1M (($0.05) diluted EPS); non-GAAP diluted EPS $0.72, up 36.4% from $0.53.
- Non-GAAP adjusted EBITDA $166.6M, or 27.5% of net sales.
- FY2024 revenue guidance raised to $2.460-2.485B; non-GAAP EPS guidance raised to $2.75-2.85.
- Integration of NuVasive progressing; management cites strong surgeon and sales force retention.

## SEC filing metadata
- accession: 0001562762-24-000124
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000124/0001562762-24-000124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000124/gmed-20240507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-24-000124
- JSON: https://secwatch.observer/filing/0001562762-24-000124.json
- Plain text: https://secwatch.observer/filing/0001562762-24-000124.txt

## Key facts
- Earnings Releases
  GLOBUS MEDICAL INC reported three-month period ended March 31, 2024 results: revenue $606.7 million, net income $7.1 million net loss, EPS ($0.05).
  - Period: three-month period ended March 31, 2024
  - Revenue: $606.7 million
  - Net income: $7.1 million net loss
  - EPS: ($0.05)
  - Result: reported results
  source text: Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 3 1 , 202 4 .  · Worldwide net sales were $ 606.7 million , an increase of 119 . 3 % , or 119.8% on a constant currency basis · GAAP net loss for the quarter was $ 7. 1 million · GAAP d iluted e arnings p er share (“ EPS ”) was ( $0. 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000124/0001562762-24-000124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.